Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Scinai Immunotherapeutics Ltd. (SCNI)

Scinai receives Nasdaq deficiency notice over $2.5 million stockholders' equity rule

Negative Impact 4 of 5 legal/regulatory Written later

BiondVax Pharmaceuticals Ltd., which the filing identifies as the registrant for Scinai (SCNI), received a Nasdaq letter on May 1, 2023 saying it does not meet the $2,500,000 minimum stockholders' equity requirement for the Nasdaq Capital Market. The company reported a stockholders' deficit of $1,760,000 in its 2022 annual report, and the notice has no immediate effect on its ADSs, which continue to trade as BVXV.

Key points

  • Nasdaq letter dated May 1, 2023 cites the $2,500,000 minimum stockholders' equity requirement under Listing Rule 5550(b)(1).
  • Stockholders' deficit of $1,760,000 reported in the 10-K for the year ended December 31, 2022, filed April 17, 2023.
  • Compliance plan due to Nasdaq by June 15, 2023; if accepted, Nasdaq may grant 180 calendar days to regain compliance.
  • The company does not currently meet Nasdaq's alternative standards for market value of listed securities or net income from continuing operations.

The filing

CompanyScinai Immunotherapeutics Ltd. (SCNI)
Form8-K, current report
Filed with the SECMay 4, 2023, 4:30 PM ET
Accession number0001213900-23-036435

Items reported: 3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.